Background: With the appearance of the SARS-CoV-2 Omicron variant the high rate of vaccination breakthroughs showed that current vaccines against COVID-19 can no longer provide adequate protection against infection. However, it is still assumed that vaccination might have a positive effect on the course of the disease. In Germany, general practitioners and specialists are usually the first treatment providers for acute illnesses. In addition, patients with infections of the upper respiratory tract often primarily consult an ear, nose and throat specialist. Most of the Omicron-infected people have a mild course of the disease and, if necessary, receive medical care on an outpatient basis. Little is known about the effectiveness of corona vaccinations on Omicron infections in relation to the clinical symptoms. In our outpatient office, we recorded a sharp increase of corona positive Omicron-infections in the beginning of 2022, despite of vaccinations against COVID-19. In a retrospective analysis, we evaluated the data of our SARS-CoV-2 tested patients with regard to clinical symptoms reported and vaccination status. The focus was particularly on the question to what extent the vaccination status in the case of Omicron infections influences the symptoms of the disease. Methods: We retrospectively evaluated the data of all patients in the first quarter of 2022 who were suspected for COVID-19. At that time, the Omicron variant was dominant in Germany. Clinical symptoms, cycle threshold (Ct) values, and the vaccination status were recorded. Symptomatic patients who tested negative for SARS-CoV-2 served as a control group. Results: Of the total cohort (n = 353), 241 (68%) patients were tested SARS-CoV-2 positive. The symptoms of the corona-positive patients were essentially similar to those of a mild to moderate cold, but compared to SARS-CoV-2-negative patients (n = 69) with a clear shift in favor of fever (35% versus 16%), cough (76% versus 52%) and increased feeling of illness (59% versus 43%), respectively. Ct values revealed no difference between unvaccinated (mean 19.15; SD 3.52) and vaccinated cases (mean 18.15; SD 3.87; p = 0.272). There was no significant correlation between the vaccination status and clinical symptom score in different age groups (age 12 to 17, r (28) = 0.26, p = 0.26; age > 18 to 60, r (191) = 0.06, p = 0.378). Conclusions: According to our results with infections with the Omicron variant, there were no differences between unvaccinated and vaccinated patients
References
[1]
Robert-Koch-Institut (2021) Epidemiologischer Steckbrief zu SARS-CoV-2 und COVID-19. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html retrieved on 21.09.2022
[2]
WHO (2022) Coronavirus Definition. https://www.who.int/health-topics/coronavirus#tab = tab_1
[3]
WHO (2023) Tracking Sars-CoV-2-Variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants
[4]
Robert-Koch-Institut (2022) Wöchentlicher Lagebericht des RKIzur Coronavirus-Krankheit-2019 (COVID-19). 07.04.2022—Aktualisierter Stand für Deutschland. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2022-04-07.pdf?__blob=publicationFile
[5]
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C.N.J., Amirthalingam, G., Edmunds, M., Zambon, M., Brown, K.E., Hopkins, S., Chand, M. and Ramsay, M. (2021) Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. The New England Journal of Medicine, 385, 585-594. https://doi.org/10.1056/NEJMoa2108891
[6]
Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E., Rubin, C., Indenbaum, V., Tal, I., Zavitan, M., Zuckerman, N., Bar-Chaim, A., Kreiss, Y. and Regev-Yochay, G. (2021) Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. The New England Journal of Medicine, 385, 1474-1484. https://doi.org/10.1056/NEJMoa2109072
[7]
Ventura, M.I., Azizian, A., Evans, S.E., Velasquez, S., Arguello, J.C. and Warburton, K. (2022) Vaccine Breakthrough Infections with SARS-CoV-2. Why Older Adults Need Booster Vaccinations. Public Health in Practice, 4, Article 100307. https://doi.org/10.1016/j.puhip.2022.100307
[8]
Chenchula, S., Karunakaran, P., Sharma, S. and Chavan, M. (2022) Current Evidence on Efficacy of COVID-19 Booster Dose Vaccination against the Omicron Variant: A Systematic Review. Journal of Medical Virology, 94, 2969-2976. https://doi.org/10.1002/jmv.27697
[9]
Bundesministerium für Gesundheit (2022) Zweite Verordnung zur Änderung der Coronavirus-Impfverordnung und der Coronavirus-Testverordnung. https://www.bundesanzeiger.de/pub/publication/L8j5aKFwiCNB9uZaVlc/content/L8j5aKFwiCNB9uZaVlc/BAnz%20AT%2010.01.2022%20V1.pdf?inline
[10]
Bundesministerium für Gesundheit (2022) Erste Verordnung zur Änderung der Coronavirus-Testverordnung vom 11. https://www.bundesanzeiger.de/pub/publication/aTAJMAnFbAMW0fJZHfr/content/aTAJMAnFbAMW0fJZHfr/BAnz%20AT%2011.02.2022%20V1.pdf?inline
[11]
Robert-Koch-Institut (RKI) (2021) Hinweise zur Testung von Patienten auf Infektion mit dem neuartigen Coronavirus SARS-CoV-2. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Vorl_Testung_nCoV.html;jsessionid=171B344CBD0F6E16D782F263DA735EB8.internet071?nn=13490888#doc13490982bodyText2
[12]
Bioscientia (2020) Was bedeuten die Begriffe Dual-Target-PCR und Ct-Wert? https://www.bioscientia.de/home/aktuelles/2020/07/was-bedeuten-die-begriffe-dual-target-pcr-und-ct-wert/
[13]
Ade, C., Pum, J., Abele, I., Raggub, L., Bockmühl, D. and Zöllner, B. (2021) Analysis of Cycle Threshold Values in SARS-CoV-2-PCR in a Long-Term Study. Journal of Clinical Virology, 138, Article ID: 104791. https://doi.org/10.1016/j.jcv.2021.104791
[14]
Brinkmann, C., Gohl, P., Mack, D., Pfeifer, J., et al. (2022) The Importance of Effect Sizes When Comparing Cycle Threshold Values of SARS-CoV-2 Variants. PLOS ONE, 17, e0271808. https://doi.org/10.1371/journal.pone.0271808
[15]
Young, B.E., Ong, S.W.X., et al. (2020) Viral Dynamics and Immune Correlates of COVID-19 Disease Severity. Clinical Infectious Diseases, 73, e2932-e2942.
[16]
European Medicines Agency (EMA) (2022) Science Medicines Health, COVID-19 vaccines: Vaccines Authorised in the European Union (EU) to Prevent COVID-19, Following Evaluation by the European Medicines Agency (EMA). https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#originally-authorised-covid-19-vac
Maslo, C., Friedland, R., Toubkin, M., Laubscher, A., Akaloo, T. and Kama, B. (2022) Characteristics and Outcomes of Hospitalized Patients in South Africa during the COVID-19 Omicron Wave Compared With Previous Waves. JAMA, 327, 583-584. https://doi.org/10.1001/jama.2021.24868
[20]
Waasila, J., Karim, S.S.A., Mudara, C., Welch, R., Ozougwu, L., Groome, M.J., et al. (2022) Clinical Severity of COVID-19 in Patients Admitted to Hospital during the Omicron Wave in South Africa: A Retrospective Observational Study. The Lancet, 10, e961-e969. https://doi.org/10.1016/S2214-109X(22)00114-0
[21]
Modes, M.E., Directo, M.P., Melgar, M., Johnson, L.R., Yang, H., Chaudhary, P., Bartolini, S., Kho, N., Noble, P.W., Isonaka, S. and Chen, P. (2022) Clinical Characteristics and Outcomes among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection during Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance—One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. The Morbidity and Mortality Weekly Report, 71, 217-223. https://doi.org/10.15585/mmwr.mm7106e2
[22]
Menni, C., Valdes, A.M., Polidori, L., Antonelli, M., Penamakuri, S., Nogal, A., Louca, P., May, A., Figueiredo, J.C., Hu, C., Molteni, E., Canas, L., Österdahl, M.F., Modat, M., Sudre, C.H., Fox, B., Hammers, A., Wolf, J., Capdevila, J., Chan, A.T., David, S.P., Steves, C.J., Ourselin, S. and Spector, T.D. (2022) Symptom Prevalence, Duration, and Risk of Hospital Admission in Individuals Infected with SARS-CoV-2 during Periods of Omicron and Delta Variant Dominance a Prospective Observational Study from the ZOE COVID Study. The Lancet, 399, 1618-1624. https://doi.org/10.1016/S0140-6736(22)00327-0
[23]
Tropeninstitut.de: Welt (2022) Studien zum Krankheitsverlauf bei Omikron. https://tropeninstitut.de/aktuelle-krankheitsmeldungen/31.12.2021-welt-omikron. Retrieved on 04.10.2022
[24]
Malik, J.A., Ahmed, S., Mir, A., Shinde, M., Bender, O., Alshammari, F., Ansari, M. and Anwar, S. (2022) The SARS-CoV-2 Mutations versus Vaccine Effectiveness. New Opportunities to New Challenges. Journal of Infection and Public Health, 15, 228-240. https://doi.org/10.1016/j.jiph.2021.12.014
[25]
Pfizer Press Release (2022) Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response against Omicron. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19. Retrieved on 04.10.2022
[26]
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., et al. (2022) Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. The New England Journal of Medicine, 386, 1532-1546. https://doi.org/10.1056/NEJMoa2119451
[27]
Külper-Schiek, W., Piechotta, V., Pilic, A., Batke, M., Dreveton, L.S., Geurts, B., Koch, J., Köppe, S., Treskova, M., Vygen-Bonnet, S., Waize, M., Wichmann, O. and Harder, T. (2022) Facing the Omicron Variant—How Well Do Vaccines Protect against Mild and Severe COVID-19? Third Interim Analysis of a Living Systematic Review. Frontiers in Immunology, 13, Article 940562. https://doi.org/10.3389/fimmu.2022.940562
[28]
Robert Koch Institute (2021). https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2021-08-16.html
[29]
Martin, D., Fischbach, D., Steuber, C., et al. (2000) Corona bei Kindern Die Co-Ki Studie. Relevanz von SARS-CoV-2 in der ambulanten pädiatrischen Versorgung in Deutschland. Monatsschrift Kinderheilkunde, 169, 39-45. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607899/ Retrieved 04.04.2021
[30]
Singanayagam, A., Patel, M., Charlett, A., Lopez Bernal, J., Saliba, V., Ellis, J., Ladhani, S., Zambon, M. and Gopal, R. (2021) Duration of Infectiousness and Correlation with RT-PCR Cycle Threshold Values in Cases of COVID-19, England, January to May 2020. Eurosurveilance, 25, Article ID: 2001483. https://doi.org/10.2807/1560-7917.ES.2020.25.32.2001483
[31]
Bundesministerium für Gesundheit (2021) Zusammen Gegen Corona: Labortest/PCR-Test. https://www.zusammengegencorona.de/faqs/testen/labortest-pcr-test/
[32]
Aranha, C., Patel, V., Bhor, V. and Gogoi, D. (2021) Cycle Threshold Values in RT-PCR to Determine Dynamics of SARS-CoV-2 Viral Load: An Approach to Reduce the Isolation Period for COVID-19 Patients. Journal of Medical Virology, 93, 6794-6797. https://doi.org/10.1002/jmv.27206
[33]
Vierbaum, L., Wojtalewicz, N., Grunert, H.P., Lindig, V., Duehring, U., et al. (2022) RNA Reference Materials with Defined Viral RNA Loads of SARS-CoV-2—A Useful Tool towards a Better PCR Assay Harmonization. PLOS ONE, 17, e0262656. https://doi.org/10.1371/journal.pone.0262656
[34]
Fall, A., Eldesouki, R.E., Sachithanandham, J., Morris, C.P., Norton, J.M., Gaston, D.C., Forman, M., Abdullah, O., Gallagher, N., Li, M., Swanson, N.J., Pekosz, A., Klein, E.Y. and Mostafa, H.H. (2022) The Displacement of the SARS-CoV-2 Variant Delta with Omicron: An Investigation of Hospital Admissions and Upper Respiratory Viral Loads. eBioMedicine, 79, Article ID: 104008. https://doi.org/10.1016/j.ebiom.2022.104008
[35]
Paparoupa, M., Schröder, A.S., Braunsteiner, J., Addo, M.M., Lütgehetmann, M., Roedl, K., Kluge, S., Ondruschka, B. and Wichmann, D. (2022) The Effects of SARS-CoV-2 Virus Type and of Vaccination Status on Causes of Death over the Course of the COVID-19 Pandemic. Deutsches Ärzteblatt International, 119, 607-608. https://doi.org/10.3238/arztebl.m2022.0255
[36]
Cohen, J.M., Carter, M.J., Cheung, C.R., Ladhani, S. and Evelina Paediatric Inflammatory Multisystem Syndrome Temporally Related to SARS-CoV-2 (PIMS-TS) Study Group (2023) Lower Risk of Multisystem Inflammatory Syndrome in Children with the Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2. Clinical Infectious Diseases, 76, e518-e521. https://doi.org/10.1093/cid/ciac553
[37]
Antonelli, M., Pujol, J.C., Spector, T.D., Ourselin, S. and Steves, C.J. (2022) Risk of Long COVID Associated with Delta versus Omicron Variants of SARS-CoV-2. The Lancet, 399, 2263-2264. https://doi.org/10.1016/S0140-6736(22)00941-2
